Key result
Targeted deletion or siRNA-mediated reduction of nmMLCK significantly reduced lung inflammation and airway hyperresponsiveness in mice, whereas its overexpression increased asthma severity.
Why the study?
Does modulation of nonmuscle myosin light chain kinase (nmMLCK) affect asthmatic inflammation in murine models?
Does modulation of nonmuscle myosin light chain kinase (nmMLCK) affect asthmatic inflammation in murine models?
This study identifies nonmuscle myosin light chain kinase (nmMLCK) as a novel molecular target that positively regulates asthmatic inflammation in murine models.
nmMLCK modulation may attenuate murine asthma features; hypothesis-generating for human trials and should not yet change practice.
Myosin light chain kinase (MLCK; gene code, MYLK) is a multifunctional enzyme involved in isoform-specific nonmuscle (nm) and smooth muscle contraction, inflammation, and vascular permeability, processes directly relevant to asthma pathobiology. In this report, we highlight the contribution of the nm isoform (nmMLCK) to asthma susceptibility and severity, supported by studies in two lines of transgenic mice with knocking out nmMLCK or selectively overexpressing nmMLCK in endothelium. These mice were sensitized to exhibit ovalbumin-mediated allergic inflammation. Genetically engineered mice with targeted nmMLCK deletion (nmMLCK(-/-)) exhibited significant reductions in lung inflammation and airway hyperresponsiveness. Conversely, mice with overexpressed nmMLCK in endothelium (nmMLCK(ec/ec)) exhibited elevated susceptibility and severity in asthmatic inflammation. In addition, reduction of nmMLCK expression in pulmonary endothelium by small interfering RNA results in reduced asthmatic inflammation in wild-type mice. These pathophysiological assessments demonstrate the positive contribution of nmMLCK to asthmatic inflammation, and a clear correlation of the level of nmMLCK with the degree of experimental allergic inflammation. This study confirms MYLK as an asthma candidate gene, and verifies nmMLCK as a novel molecular target in asthmatic pathobiology.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2014) studied Asthmatic inflammation. nmMLCK deletion, overexpression, or siRNA reduction vs. Wild-type/control mice was evaluated on Lung inflammation and airway hyperresponsiveness. Targeted deletion or siRNA-mediated reduction of nmMLCK significantly reduced lung inflammation and airway hyperresponsiveness in mice, whereas its overexpression increased asthma severity.